文献速递前列腺增生与排尿功能障碍

第二代临时植入镍钛装置治疗BPO相关LUTS的3年结果

3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-10-01

36个月时50例可评估患者的IPSS、QoL、Qmax和PVR较基线显著改善,无晚期并发症、射精功能障碍或额外治疗失败。

要点

  • iTIND在3年随访中维持稳定疗效,IPSS、QoL、Qmax和PVR均显著优于基线。
  • 12至36个月间未观察到晚期术后并发症。
  • 性功能保持稳定,无性功能障碍或射精功能障碍报告。

核心结论

  • iTIND治疗BPO相关LUTS在3年随访中显示出显著且持久的症状缓解和功能参数改善。

研究设计与样本

  • 受试者洗脱α受体阻滞剂1个月和5α还原酶抑制剂6个月,植入在轻度镇静下进行,5-7天后局部麻醉下取出。

主要发现

  • 36个月功能结果可评估50例患者,平均IPSS为8.55±6.38,较基线改善-58.2%(p<0.0001)。
  • 平均QoL为1.76±1.32,较基线改善-55.6%(p<0.0001)。
  • 平均Qmax为15.2±6.59 ml/s,较基线改善+114.7%(p<0.0001)。
  • 平均PVR为9.38±17.4 ml,较基线改善-85.4%(p<0.0001)。
  • 意向性治疗分析(ITT)同样证实36个月功能结果较基线显著改善(均p<0.0001)。

临床怎么用

  • 对于BPO相关LUTS男性,iTIND可作为维持3年症状和功能改善的微创治疗选择。
  • 术后3年内无需担心晚期并发症、射精功能障碍或额外治疗失败。

局限性

  • 单臂设计缺乏对照组。
  • 36个月功能结果仅50例可评估,存在失访偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To report the 3-year results of a prospective, single arm, multicenter, international clinical study with the second generation of the temporary implantable nitinol device (iTIND; Medi-Tate Ltd®, Israel) on men suffering lower urinary tract symptoms (LUTS) secondary to benign prostatic obstruction (BPO). METHODS: Eighty-one men with symptomatic BPO (IPSS ≥ 10, peak urinary flow <12 ml/s, and prostate volume <75 ml) were enrolled in this study between December 2014 and December 2016. Subjects were washed-out 1 month for alpha-blockers and 6 months for 5-ARIs. The implantation was performed under light sedation and the removal 5-7 days later with topical anesthesia. Perioperative results including OR-time, pain (VAS) postoperative complications (Clavien-Dindo-Grading System), functional results (Qmax, IPSS, PVR) and quality of life (QoL) were assessed at 1, 3, 6 months, 1, 2, and 3 years. Sexual and ejaculatory function were evaluated using two yes/no questions. RESULTS: Thirty-six month functional results were available for 50 patients and demonstrated that iTIND efficacy remained stable through 3 years, with averages IPSS, QOL, Qmax and PVR of 8.55 + 6.38, 1.76 + 1.32, 15.2 + 6.59 ml/s and 9.38 + 17.4 ml, improved from baseline by -58.2, -55.6, +114.7, and -85.4% (all significantly different from their corresponding baseline values, p < 0.0001). Even considering the Intention to Treat analysis (ITT), the 36-month results confirmed significant improvements of the functional outcomes if compared with baselines values (all p < 0.0001). No late post-operative complications were observed between 12 and 36 months. Sexual function was stable through 3 years, with no reports of sexual or ejaculatory dysfunctions. No patients underwent alternative treatments between 24 and 36 months. CONCLUSION: Treatment of BPO-related LUTS with iTIND demonstrated a significant and durable reduction in symptoms and improvement of functional parameters and quality of life at 3 years of follow-up. No late post-operative complications, ejaculatory dysfunction or additional treatment failures were observed between 24 and 36 months.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Amparore D, Fiori C, Valerio M, et al. 3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction. Prostate Cancer Prostatic Dis. 2020. PMID: 33005003. doi:10.1038/s41391-020-00281-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。